The other opportunity of clinical adoption of some HSP70 inhibitors against breast cancer may become the development and use of certain methods for targeted delivery of the inhibiting agent to the tumor cells in order to restrict the HSP70 inhibition-associated cytotoxic effects outside the tumor. This evidence concerns the gene HSPA1A and breast carcinoma.